September 6, 2016:

Defymed is nominated for the Medstartup awards 2016, an initiative of the Galien Foundation & Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry.

In the frame of this contest, Defymed collaborates with Semma Therapeutics to obtain a preclinical validation of stem cell derived insulin secreting cells in the bioartificial pancreas MailPan ®.

The winners will be announced and recognized by a World Renown Scientific Committee on October 27, 2016 at MedStartUp Awards Ceremony at the Alexandria Life Sciences Center & the American Museum of Natural History in New York City. For more info